Almost 10 months after the National Institute for Health and Care Excellence (NICE), the British Thoracic Society (BTS), and the Scottish Intercollegiate Guidelines Network (SIGN) released an updated joint guideline for asthma care and management, a major milestone has been hit. Over 1 million people are now using combination inhalers instead of relying solely on blue reliever inhalers, marking a major shift towards inflammation-focused asthma management.1

Why does this matter?

Previously, many people living with asthma relied on their blue reliever inhaler, which relieved symptoms, making them feel better quickly. The problem with this was that whilst symptoms were being addressed, the underlying airway inflammation, the main driver of their symptoms, was not being treated. If the inflammation is not treated, symptoms continue to recur, damaging quality of life and increasing over-reliance on medication.1

The problem with symptom-led asthma care.

Patients who rely heavily on Short-Acting Beta-Agonist (SABA) inhalers (rescue inhalers) may report feeling well and believe that their asthma is well controlled because regular use of their inhaler keeps their symptoms at bay.1 When, in reality, this reliance is masking the underlying issue: airway inflammation.

Combination Asthma Inhaler - FeNO and modern asthma care
Airway Inflammation Infographic

Airway inflammation cannot always be felt, and if left untreated, it could lead to further exacerbations, including asthma attacks.

The shift towards prevention-focused care.2

The update to the guideline placed greater emphasis on treating the underlying inflammation rather than just the symptoms, demonstrating an evolution in asthma care. The updated guidance reflects:

  • Earlier anti-inflammatory treatment,
  • Reduced SABA reliance,
  • Prevention of exacerbations,
  • More proactive asthma management.

The impact of this guidance is clear: over 1 million people now use combination inhalers to relieve symptoms and treat underlying inflammation, a significant milestone for asthma care.1

Why objective insight matters.

During routine asthma reviews, patients are typically asked about their symptoms, which rely on patient recall. Typically, people with asthma downplay their symptoms, believing that what they experience is typical of their condition.3

And whilst peak flow remains a useful tool in asthma care, it alone may not provide the full picture. It measures airflow obstruction, rather than the inflammatory activity driving asthma, demonstrating the need for objective assessment, because better asthma care starts with better insight.

The role of FeNO testing.2

Fractional exhaled Nitric Oxide (FeNO) testing provides an objective tool to measure airway inflammation. It is non-invasive, easy to do at the point of care and supports:

  • Diagnosis,
  • Inhaled corticosteroid (ICS) decisions,
  • Adherence assessment,
  • Monitoring,
  • Evaluation of exacerbation risk.

Aligning with the latest guidance, FeNO supports the move towards more personalised, biomarker-driven asthma care.

The NObreath® FeNO device.

The NObreath® is a modern FeNO device; it is portable and easy to use, making it perfect for primary care. Clinicians can measure a person’s airway inflammation in a short amount of time, fitting perfectly into a standard healthcare appointment. This objective insight enables clinicians to make informed decisions there and then without the need for a follow-up appointment to discuss results.

Combined with an extensive clinical history, a FeNO test with the NObreath® can aid in an asthma diagnosis and tailor treatment appropriately, providing enhanced asthma monitoring.

Precision medicine and the future of asthma care.2

Guidelines are updated as technology and research evolve to improve patient care. The latest guideline from NICE/BTS/SIGN marked a move towards:

Taking a FeNO test with the NObreath
  • Precision medicine,
  • Biomarkers
  • Personalised pathways
  • Earlier intervention,
  • Better outcomes.

The move towards combination inhalers marks more than a treatment change; it represents a broader evolution in how asthma is understood and managed. Objective insight can provide clinicians with a better understanding of what is going on beneath the surface, with FeNO testing supporting this objective insight and supporting future asthma care.

As asthma care continues to evolve, understanding airway inflammation will become increasingly important in helping clinicians deliver a more personalised and proactive approach.

To learn more about the NObreath® device and how FeNO testing is improving patient outcomes worldwide, visit the website here.

References

  1. “I no longer feel asthmatic”: more than a million people now using new style inhalers [Internet]. NICE website: The National Institute for Health and Care Excellence. NICE; 2026. Available from: https://www.nice.org.uk/news/articles/-i-no-longer-feel-asthmatic-more-than-a-million-people-now-using-new-style-inhalers
  2. National Institute for Health and Care Excellence. Overview | Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) | Guidance | NICE [Internet]. Nice.org.uk. NICE; 2024. Available from: https://www.nice.org.uk/guidance/NG245
  3. Bidad N, Barnes N, Griffiths C, Horne R. Understanding patients’ perceptions of asthma control: a qualitative study. European Respiratory Journal. 2018 May 17;51(6):1701346.

Tobacco kills more than 7 million people each year, including an estimated 1.6 million non-smokers exposed to second-hand smoke.1 It is estimated that tobacco costs the global economy more than $1.4 trillion a year in healthcare costs and lost productivity.2 This World No Tobacco Day, we are going to explore the appeal behind smoking tobacco and the healthcare burden it causes.

What is World No Tobacco Day?3

World No Tobacco Day is a global awareness event, held every year on the 31st May by the World Health Organisation (WHO). The event was created to draw global attention to the tobacco epidemic and the preventable deaths and diseases it causes. Each year follows a new theme; the theme for 2026 is Unmasking the appeal – countering nicotine addiction. Whilst global tobacco use has declined in recent years, its burden remains devastating.

The appeal: Why tobacco still attracts users.

Cigarette in a hand

Whilst evidence does not support this, smoking is still widely perceived as a stress reliever, with studies indicating that between 36-43% of people believe smoking helps manage stress, anxiety and depression. The truth is, smoking actually increases tension and lowers mental health in the long run.4

Marketing tactics have changed over the years with the introduction of vapes, flavoured products, and targeting youth and young adults, especially in low-income communities and regions with weaker tobacco regulations.

Together, these psychological misconceptions and evolving marketing strategies create a powerful and carefully engineered appeal. Nicotine products are framed as tools for coping, symbols of independence, or fashionable accessories, rather than addictive substances. These influences normalise use, particularly among younger and more vulnerable populations, making tobacco appear not only acceptable but desirable.

The health burden: What tobacco really costs.

Smoking tobacco has a direct impact on health and is linked to diseases like:5

  • Lung cancer,
  • Chronic obstructive pulmonary disease (COPD),
  • Coronary artery disease,
  • Stroke.

This doesn’t just impact the smokers themselves; non-smokers are also affected by second-hand smoke, leading to a significant impact on healthcare systems worldwide.

Smoking-related hospital admissions and care in the UK alone cost the NHS £1.9 billion each year, signifying an urgent need for change.6

What needs to change?

There are many contributing factors that could change and improve outcomes worldwide, and whilst there are already various initiatives in place, such as:

  • Plain packaging,
  • Smoke-free zones,
  • Less advertisement.

More can be done across the board to remove the appeal.

Awareness campaigns like World No Tobacco Day help to raise awareness of the significant impact smoking can have on health and economic costs. Additionally, smoking cessation programmes can provide support for those looking to quit smoking. These services can educate smokers on the long-term benefits of quitting smoking as well as highlight tools which can aid a quit attempt. One of those tools is carbon monoxide (CO) monitoring.

What is CO monitoring?

Taking a CO test with the Smokerlyzer

When someone smokes tobacco, they inhale CO, which enters their bloodstream and reduces oxygen delivery around the body.7 A CO monitoring device like the Smokerlyzer® measures CO levels in a person’s exhaled breath. The Smokerlyzer® is widely used across the world as a motivational tool to aid a quit-smoking attempt. Seeing CO levels drop empowers smokers to continue their quit-smoking journey.

Smokerlyzer Range

A 2012 study found that people who used a CO monitoring device reported feeling more motivated to quit smoking. Participants described how seeing their CO levels decrease over time provided clear, tangible evidence that their efforts were making a real difference. This immediate, visible feedback appeared to strengthen their commitment to quitting by reinforcing the health benefits of staying smoke-free and encouraging them to keep going, especially during moments of doubt or temptation.8

World No Tobacco Day 2026 is highlighting how the appeal to nicotine and tobacco addiction is engineered and not accidental. With healthcare and economic costs rising, it is vital that more is done to tackle the tobacco epidemic.

To learn more about the support available to aid a quit smoking attempt, visit the NHS website here.

To find out more about the Smokerlyzer® range and how it is helping people quit smoking for good, visit the website here.

References

  1. World Health Organization. Tobacco [Internet]. World Health Organization. World Health Organization; 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/tobacco
  2. ‌US$ 1.4 trillion lost every year to tobacco use – New tobacco tax manual shows ways to save lives, money and build back better after COVID-19 [Internet]. www.who.int. Available from: https://www.who.int/news/item/12-04-2021-1.4-trillion-lost-every-year-to-tobacco-use-new-tobacco-tax-manual-shows-ways-to-save-money-and-build-back-better-after-covid-19
  3. ‌World. World No Tobacco Day 2026: Unmasking the appeal – countering nicotine and tobacco addiction [Internet]. Who.int. World Health Organization: WHO; 2025. Available from: https://www.who.int/news/item/17-10-2025-world-no-tobacco-day-2026–unmasking-the-appeal—countering-nicotine-and-tobacco-addiction
  4. ‌Perski O, Theodoraki M, Cox S, Kock L, Shahab L, Brown J. Associations between smoking to relieve stress, motivation to stop and quit attempts across the social spectrum: A population survey in England. Kaye JT, editor. PLOS ONE [Internet]. 2022 May 17;17(5):e0268447. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0268447
  5. ‌ASH. Smoking and Other Health Conditions – ASH [Internet]. ASH. 2025. Available from: https://ash.org.uk/resources/view/smoking-and-other-health-conditions
  6. ‌Action on Smoking and Health. Latest figures show cost of smoking in England up 25% to at least £21.8 billion [Internet]. ASH. 2024. Available from: https://ash.org.uk/media-centre/news/press-releases/latest-figures-show-cost-of-smoking-in-england-up-25-to-at-least-21-8-billion
  7. ‌Raub JA, Benignus VA. Carbon monoxide and the nervous system. Neuroscience and Biobehavioral Reviews [Internet]. 2002 Dec 1;26(8):925–40. Available from: https://pubmed.ncbi.nlm.nih.gov/12667497/
  8. ‌Beard E, West R. Pilot study of the use of personal carbon monoxide monitoring to achieve radical smoking reduction. Journal of Smoking Cessation. 2012 Jun;7(1):12-7.

Demonstrating innovations in respiratory and allergy diagnostics with the NObreath® and Gastrolyzer® range.

Bedfont® Scientific Ltd., an innovative leader in the medical breath analysis industry with almost 50 years of experience, is pleased to join thousands of healthcare experts at this year’s European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026 at stand I03 to showcase its NObreath® and Gastrolyzer® range of non-invasive breath analysis devices.

The congress, taking place in Istanbul, Türkiye from Friday 12th to Sunday 14th of June, is widely recognised as the world’s largest and most influential meeting dedicated to allergy and clinical immunology. It brings together thousands of clinicians, researchers and healthcare professionals from across the globe each year to share new ideas and showcase innovations in diagnostics, playing a central role in advancing research, education and patient care in allergic diseases such as asthma and food allergy.

“Attending the EAACI Congress 2026 reflects our commitment to strengthening our global network. We look forward to connecting with like-minded organisations, sharing insights into our technology, and exploring new distribution partnerships with those seeking innovative solutions.” Said Jason Smith, CEO at Bedfont®. “We see EAACI as a key opportunity to build relationships that will drive future growth in the allergy and immunology space.”

The Bedfont® team is pleased to be joined by its Turkish distributor, Teknikel, to demonstrate its Fractional exhaled Nitric Oxide (FeNO) and hydrogen and methane breath testing (HMBT) technologies, highlighting how these innovative tools can support improved diagnosis, monitoring, and the management of respiratory and gastrointestinal conditions.

The team will be at stand I03, where you can find the NObreath® FeNO device, which has been improving asthma care and management for over 15 years, providing an objective insight into airway inflammation, a key driver of asthma symptoms. And the Gastrolyzer® range of HMBT devices, which have been aiding gastrointestinal investigation for over 35 years, enabling clinicians to tailor treatment effectively.

For Bedfont®, this congress is invaluable not only for showcasing its solutions but also for engaging with partners and stakeholders as it continues to advance technology and expand its global reach. To learn more, visit the website here.

Bedfont® Team at EAACI 2025

Bedfont® celebrates global expansion by delivering UK healthcare solutions to a growing global audience.

SEHTA Export Finalist - Bedfont® Recognised

Bedfont® Scientific Limited, an innovative MedTech company that specialises in designing and manufacturing medical breath analysis devices, is thrilled to have been shortlisted in the Export Achievement category at the Science and Engineering Health Technologies Alliance (SEHTA) Healthcare Business Awards 2026.

The SEHTA Healthcare Business Awards are one of the South East’s leading healthcare innovation awards, celebrating excellence in healthcare, especially in life sciences and medical technology. Bedfont®, a world leader in breath analysis, has seen significant growth over the last decade and places a strong emphasis on international sales, with over 59% of export sales contributing to its annual turnover.

Jason Smith, CEO at Bedfont®, comments, “Being shortlisted for the Export Achievement award is a fantastic recognition of our team’s hard work and our mission to improve healthcare outcomes globally. Our international growth is a key part of our strategy, and we’re proud to represent UK innovation on the world stage.”

With a global network of over 100 distributors, Bedfont® prioritises long-term partnerships built on trust and collaboration. The company understands that entering new markets is a gradual process, requiring sustained investment in relationships and a tailored approach to each region. By adapting its service, support, and go-to-market strategy to local needs, Bedfont® ensures its solutions are both relevant and effective worldwide.

The awards ceremony, due to take place at Scale Space, Imperial College London, on Tuesday, 26th May, will bring together businesses across the South East to celebrate healthcare innovation. To find out more about Bedfont® and its innovative medical devices, visit the website here.

Bedfont® Scientific Limited to showcase why the NObreath® is the FeNO device of choice at this year’s global event.

World leaders in breath analysis Bedfont® Scientific Ltd. are pleased to be attending this years American Thoracic Society (ATS) International Conference, to exhibit the innovative NObreath® Fractional exhaled Nitric Oxide (FeNO) device at booth 1236 alongside its US distributor coVita™. Bedfont® is an innovative MedTech company with nearly 50 years of expertise in the design and manufacture of medical breath analysis devices, helping to improve patient outcomes worldwide.

The ATS International Conference, taking place from the 15th and 20th May at the Orange County Convention Centre in Orlando, Florida, is a global event attracting more than 15,000 experts in pulmonary, critical care and sleep medicine to share groundbreaking research and advance clinical practice. Bedfont® will be sharing how the NObreath® is revolutionising asthma care worldwide.

The team can be found at booth 1236, where they will showcase the NObreath®, which has been helping to improve asthma care and management for over 15 years by providing objective insight into airway inflammation, a key feature of asthma. It enables clinicians to measure inflammation non-invasively, supporting a future where today’s science meets tomorrow’s care.

“We’re excited to be part of ATS this year and to bring our expert team together on the stand to engage with the global respiratory community. We invite attendees to come and speak with us, experience our technology firsthand, and explore how we can work together.” Said Jason Smith, CEO at Bedfont®. “ATS provides an important platform for us to showcase the NObreath® and its impact in respiratory care.” 

Bedfont team at ATS 2025

Joining Bedfont® and coVita™ at booth 1236 is Medical Advisory Board Member, Carol Stonham MBE, a respiratory expert who serves as the Children and Young People Asthma Clinical Lead at Gloucestershire ICB. Carol will be bringing a wealth of knowledge to the event and will be hosting a talk at Innovation Hub 3 on Sunday 17th May at 1:15 pm EDT; where she will explore the role of FeNO in practice and discuss emerging opportunities.

You will find the Bedfont® team at booth 1236 between the 17th and 19th May, to find out more visit the website here.

In 2019, 262 million people worldwide had asthma, with 455,000 deaths from the chronic condition1, stark figures that highlight asthma control still needs improvement. Most people living with asthma believe that no physical symptoms mean their asthma is controlled, but this is sadly not always the case. Airway inflammation is the underlying cause of asthma, something that cannot be seen and not always felt.

Many asthma patients feel fine until they don’t. Objectively measuring airway inflammation with Fractional exhaled Nitric Oxide (FeNO) testing is a vital way to prevent exacerbations and improve overall asthma care.

Airway Inflammation Infographic - Advancements in FeNO Testing

What is FeNO and why does it matter2?

When airways are inflamed, they produce excess nitric oxide (NO), a gas that can be measured by performing a FeNO test. A FeNO test provides insight into a person’s airway inflammation by measuring NO levels in exhaled breath.

  • High FeNO levels indicate eosinophilic airway inflammation. The higher the reading, the more severe the inflammation is.

By measuring airway inflammation, healthcare professionals can use the results to aid an asthma diagnosis and tailor treatment appropriately.

Limitations of traditional asthma monitoring.

Taking a FeNO test with the NObreath - Advancements in FeNO Testing

Traditionally, clinicians have relied on patients relaying their symptoms, which doesn’t always give the full picture of a person’s asthma. Many people believe that because they have asthma, they should have a cough and they should have a wheeze, and they downplay their symptoms.

Providing a FeNO test at regular asthma reviews empowers healthcare professionals to detect airway inflammation early, allowing them to monitor medication response and personalise treatment. This ultimately can catch an exacerbation early and get patients back on track with well-controlled asthma.

Additionally, medication adherence rates range from 30% to 70%3. A patient may report taking their medication regularly and using the correct technique; however, a quick, easy FeNO test can reveal poor adherence. Showing a patient their airway inflammation can create an opportunity to discuss and reinforce the importance of good adherence and technique.

Recent advancements in FeNO testing.

NObreath device - Advancements in FeNO Testing

In the 1990s, researchers found that FeNO served as a non-invasive biomarker of airway inflammation and used chemiluminescence to measure it. This method proved very costly due to regular maintenance and calibration, and difficult to access because of the machines’ size and the specialist training required.

In recent years, this has advanced to electrochemical sensor technology, enabling more cost-effective, portable FeNO devices like the NObreath®, whilst still matching the gold-standard technology of chemiluminescence. Thanks to continuous innovation, FeNO devices are now accessible at the point of care and provide instant results, improving patient outcomes.

To learn more about chemiluminescence and electrochemical sensor technology, read our article here.

In the late 1990s, FeNO began to appear in international clinical practice guidelines for asthma, and the American Thoracic Society (ATS) officially recommended its use to assess airway inflammation in adults and children in 20114.

Since then, FeNO testing has been recommended in asthma guidelines across the world, with the most recent joint guidance from the National Institute for Health and Care Excellence (NICE), the British Thoracic Society (BTS), and the Scottish Intercollegiate Guidelines Network (SIGN), recommending FeNO as a first-line test for asthma diagnosis5.

To learn more about the global guidelines on asthma care and management, read our article here.

The NObreath® FeNO device

The NObreath® was developed in 2008, designed with healthcare professionals and patients in mind. It provides a non-invasive, fairly priced option for FeNO testing, making it more accessible to healthcare providers worldwide.

Featuring an adult and child test mode, the NObreath® is suitable for all settings thanks to its accuracy and portability. It requires an exhalation-only manoeuvre, making it a quick and easy test to take for both adults and children.

The device was designed with the patient in mind and features multiple flow incentive screens. These incentive screens not only engage the patient, but they also ensure a correct flow rate of 50 ml/s, providing an accurate test result.

To learn more about FeNO testing with the NObreath®, visit the website here.

Child test with the NObreath - Advancements in FeNO Testing

Many deaths from asthma are thought to be preventable, meaning better asthma care is needed. Advances in FeNO testing have been instrumental in improving asthma control, and with increasing recognition in global asthma guidelines, FeNO testing can make a difference.

To learn more about Bedfont® Scientific Limited, world leaders in breath analysis with over 49 years of expertise in the medical device industry, visit the website here.

References

  1. World Health Organization. Asthma [Internet]. World Health Organization. 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/asthma
  2. NHS England. NHS Accelerated Access Collaborative» Fractional Exhaled Nitric Oxide (FeNO) [Internet]. www.england.nhs.uk. 2025. Available from: https://www.england.nhs.uk/aac/what-we-do/innovation-for-healthcare-inequalities-programme/rapid-uptake-products/fractional-exhaled-nitric-oxide/
  3. ‌Improving adherence in Asthma treatment | Cambridge Network [Internet]. Cambridgenetwork.co.uk. 2024. Available from: https://www.cambridgenetwork.co.uk/news/improving-adherence-asthma-treatment
  4. ‌Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. American journal of respiratory and critical care medicine [Internet]. 2011;184(5):602–15. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21885636/
  5. National Institute for Health and Care Excellence. Overview | Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) | Guidance | NICE [Internet]. Nice.org.uk. NICE; 2024. Available from: https://www.nice.org.uk/guidance/NG245

Over 28 million people in the United States (US) have asthma1,2, with the condition named as the leading chronic disease in children, affecting approximately 4.9 million under the age of 182,3. In the US, asthma is one of the most common and costly diseases, and these stark figures highlight why asthma still matters, even in 2026. This Asthma and Allergy Awareness Month, we are exploring the prevalence of asthma and how advancing technology can make a difference.

Asthma and Allergy Awareness Month

Asthma places a significant burden on healthcare and the economy, with annual economic costs between 2008 and 2013 contributing to:

  • $3 billion in losses due to missed work and school days,
  • $29 billion due to asthma-related mortality,
  • $50.3 billion in medical costs.

The numbers prove that asthma is common, but it is important to remember that this chronic condition is also manageable; however, outcomes are not equal, and certain populations are disproportionately affected. These disparities are shaped by a combination of structural, social, biological, and behavioural factors. Structural inequities, such as5:

  • Systemic racism,
  • Residential segregation,
  • Discriminatory policies,

Often influence the conditions in which people live, work, and access care. These, in turn, affect social determinants like income, education, housing quality, environmental exposures, and access to healthcare. While biological factors such as genetics and individual behaviours like smoking or medication adherence play a role, it is these broader social and structural inequities that largely drive unequal asthma outcomes across populations.

The hidden problem: Poor asthma control

Millions of people are diagnosed with asthma, with many of them not having the condition well managed. It is estimated that 44% of children with asthma have uncontrolled asthma6, which can lead to exacerbations and severe asthma attacks.

Many asthma patients rely heavily on rescue inhalers, which relieve the immediate symptoms but do not address the underlying airway inflammation. This quick relief can make patients feel in control of their asthma, but without addressing the root cause, asthma remains uncontrolled beneath the surface.

Another contributor to poorly controlled asthma is misdiagnosis. Asthma is not a single condition; it can be allergic/eosinophilic or non-eosinophilic. If the asthma is not diagnosed correctly, this can lead to ineffective or over/under treatment. If the underlying asthma type isn’t properly diagnosed, the treatment cannot be matched to the disease type.

Additionally, a lack of objective measurement in routine care can affect asthma control. Traditionally, asthma management has relied on:

  • Symptoms,
  • Patient recall,
  • Peak flow.

The problem with just focusing on these points is that clinicians may over- or underestimate control, which leads to escalating or reducing treatment inappropriately. Symptoms do not always reflect underlying inflammation and may lead to missed opportunities for early intervention.

Better Asthma Care

This is where better access to objective, point-of-care tools, such as Fractional exhaled Nitric Oxide (FeNO) testing, is needed. Without objective measurement, asthma care often relies on what can be seen and heard, not on what’s happening at the inflammatory level inside.

What is FeNO testing7?

A FeNO test is a quick, easy, non-invasive way to measure airway inflammation, specifically eosinophilic inflammation. When airways are inflamed, higher levels of nitric oxide (NO) are produced. This gas can be detected in exhaled breath, with higher levels indicating inflammation, making FeNO testing a vital tool for asthma care and management.

FeNO Testing with the NObreath®

With FeNO providing a non-invasive, quick point-of-care test, it can help identify type 2 inflammation and predict steroid responsiveness, helping clinicians see inflammation that symptoms alone cannot reveal.

How FeNO improves decision-making

FeNO fits into the whole asthma pathway; it’s not just a diagnostic tool; it can also help treat and manage asthma. Diagnosing and managing this chronic condition isn’t always straightforward, and in the past, healthcare professionals have relied on guesswork. FeNO testing changes that, it can:

  • Support a diagnosis of asthma,
  • Guide inhaled corticosteroid (ICS) use,
  • Monitor medication adherence,
  • Predict exacerbation risk,
  • Reduce unnecessary medication escalation.
Child taking a FeNO test

FeNO is recognised in global guidelines for asthma care and management, with the ATS/ERS guidance positioning FeNO as a practical tool to support diagnosis, guide anti-inflammatory treatment, and monitor airway inflammation, helping clinicians move from symptom-based to more objective asthma care8.

Expanding access to FeNO testing

Objective testing has the potential to transform asthma care, but access remains a challenge. Limited availability outside specialist centres, time constraints in primary care, and geographic inequalities have all contributed to the underuse of tools such as FeNO. The result is a gap between what is possible and what is delivered in everyday care. Advances in technology only matter if people can access them.

Bedfont® Scientific Limited, an innovative MedTech company based in the UK with nearly 50 years of experience in medical breath analysis, has been improving asthma care and management worldwide for over 15 years with its NObreath® FeNO device. Working closely with its US distributor, coVita™, it has been working hard to improve access to FeNO testing by providing a fairly priced, low-maintenance FeNO device.

In 2025, the NObreath® became the allergists’ FeNO device of choice in the US, with Allergy Partners offering FeNO testing with the NObreath® through more than 125 locations in over 20 states. This partnership ensures that FeNO testing is being integrated into routine care, not just specialist settings, allowing more patients to get tested closer to home.

The future of asthma care

This Asthma and Allergy Awareness Month, we want to focus on how early intervention can lead to better long-term outcomes for asthma patients. Advances in technology mean that objective testing, such as FeNO, is more widely accessible, which is vital as biomarker-driven care becomes the standard. FeNO devices like the NObreath® provide clinicians with more insight into underlying inflammation that cannot be seen, enabling improved patient care.

To learn more about the NObreath® FeNO device and how it is improving precision in asthma care, visit the website here.

NObreath® FeNO device

References

  1. NCHS/DHIS. NHIS Adult Summary Health Statistics [Internet]. Cdc.gov. 2021. Available from: https://data.cdc.gov/National-Center-for-Health-Statistics/NHIS-Adult-Summary-Health-Statistics/25m4-6qqq/about_data
  2. ‌NCHS/DHIS. NHIS Child Summary Health Statistics [Internet]. Cdc.gov. 2021. Available from: https://data.cdc.gov/National-Center-for-Health-Statistics/NHIS-Child-Summary-Health-Statistics/wxz7-ekz9/about_data
  3. ‌Ferrante G, La Grutta S. The Burden of Pediatric Asthma. Frontiers in Pediatrics [Internet]. 2018 Jun 22;6(186):1–7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023992/
  4. ‌Nurmagambetov T, Kuwahara R, Garbe P. The Economic Burden of Asthma in the United States, 2008–2013. Annals of the American Thoracic Society [Internet]. 2018 Mar;15(3):348–56. Available from: https://pubmed.ncbi.nlm.nih.gov/29323930/
  5. ‌Asthma and Allergy Foundation of America. Asthma Disparities in America [Internet]. Asthma & Allergy Foundation of America. 2020. Available from: https://aafa.org/asthma-allergy-research/our-research/asthma-disparities-burden-on-minorities/
  6. ‌CDC Archives [Internet]. archive.cdc.gov. Available from: https://archive.cdc.gov/#/details?url=https://www.cdc.gov/asthma/asthma_stats/uncontrolled-asthma-children-2018-2020.htm
  7. ‌What is a FeNO Test? [Internet]. Aaaai.org. 2021. Available from: https://www.aaaai.org/Tools-for-the-Public/Conditions-Library/Asthma/What-Is-A-FeNO-Test
  8. ‌Murphy RC, Zhang P, Tejwani V, Khatri SB, Hallstrand TS, Ruminjo JK, et al. Summary for Clinicians: Clinical Practice Guideline for the Use of Fractional Exhaled Nitric Oxide to Guide the Treatment of Asthma. Annals of the American Thoracic Society. 2022 Oct;19(10):1627–30.

Embedding compassion into policies, practices and everyday actions.

Bedfont® Scientific Ltd. is a world leader in breath analysis, with over 49 years of expertise in designing and manufacturing medical devices. The innovative med-tech company, based in Harrietsham, was proud to receive the Compassionate Workplace accreditation from Heart of Kent Hospice, in partnership with Compassionate Communities UK, in December 2025.

Compassionate Communities UK is a UK charity dedicated to embedding compassion into everyday life, including workplaces. The charity is collaborating with various organisations, helping employers ensure they operate in a compassionate way for staff who are dealing with bereavement, death and loss or those who may be facing a terminal illness themselves.

Heart of Kent Hospice, a charity-run hospice providing specialist palliative and end-of-life care for adults, as well as their families, carers and loved ones, is supporting employers in the local area with the tools and confidence to have compassionate conversations about end-of-life, loss and bereavement in the workplace. They were thrilled to have awarded Bedfont® with the Compassionate Workplace accreditation in December 2025.

David Dadswell, Corporate Partnerships Manager at Heart of Kent Hospice, said, “Bedfont’s commitment to becoming the first accredited Compassionate Workplace is a powerful statement. By recognising the realities of grief, caring and serious illness, they are setting a new standard for what a truly supportive employer looks like. Prioritising compassion at work will make a meaningful difference to their staff and families across our community.”

Having supported the hospice since 2023, sponsoring its flagship Bluebell Walk events and Shaun the Sheep trail, Bedfont® joined Heart of Kent Hospice for a roundtable discussion to identify areas where the hospice could provide support, such as signposting and delivering training. During the accreditation process, it was highlighted that some areas of the business required improvement, and the hospice subsequently delivered a group training session focused on those areas.

Compassionate Workplace

After completing the assessment, Bedfont® became the first business in Kent to achieve Compassionate Workplace status, underscoring the company’s commitment to providing an environment where every staff member feels valued, supported and heard.

“Receiving the Compassionate Workplace accreditation is a deeply meaningful milestone for us.” Said Jason Smith, CEO at Bedfont® Scientific. “As the first organisation in Kent to achieve this recognition, we feel both proud and responsible to lead by example. At the heart of our organisation are people, and we believe work should be a place of understanding, dignity and care, particularly during life’s most challenging moments. This accreditation strengthens our commitment to creating a culture where compassion is embedded in our leadership, our policies and our everyday actions.”

Already committed to employee wellbeing, Bedfont® has strengthened its offerings for staff, equipping them with the knowledge and tools to approach difficult conversations and support those dealing with bereavement or terminal illness.

To learn more about Bedfont® and its support of Heart of Kent Hospice, visit the website here, and follow them on LinkedIn.

Written by Dr Jafar Jafari, GI Cognition

This article reflects the opinions of a healthcare professional. The views expressed are their own. The intended use for the GastroCH4ECK® is to aid in the diagnosis of the following disorders:

  • Lactose Intolerance,
  • Small Intestinal Bacterial Overgrowth (SIBO).

Hydration and nutrition are often discussed as two separate topics. In reality, they work together every single day inside the digestive system. What we drink influences how comfortably we tolerate fibre, how easily our bowels move, and how efficiently our digestive system works. What we eat influences digestion, gas production, stool pattern, energy levels, and symptoms such as bloating or abdominal discomfort.

A simple way to think about this relationship is to imagine trying to mix ingredients in a completely dry container. Nothing moves properly. The contents simply sit there. Digestion works in a similar way: without adequate fluid, the digestive system struggles to move food smoothly through the gut. Hydration provides the medium in which digestion happens, while nutrition provides the materials the body, and the microbes in our gut, need to function.

But how do we know whether our gut is responding well to what we eat and drink? Interestingly, one of the most informative signals can come from something we rarely think about: our breath.

Your Breath as a “Thermometer” for the Gut1

One of the reasons I became so interested in hydrogen–methane breath testing (HMBT), and ultimately wrote a book about it The Essential Guide to Hydrogen and Methane Breath Testing, the book offers a unique window into how our digestive system is functioning.

Human tissues do not produce hydrogen or methane gases. These gases are produced when microorganisms in the gut ferment carbohydrates that escape digestion. Some of this gas enters the bloodstream and eventually reaches the lungs, where it is exhaled in our breath. By measuring hydrogen and methane in breath samples over time, clinicians can gain insight into microbial fermentation patterns in the gut.

In a way, breath testing acts like a thermometer for gut activity. Just as a thermometer shows how the body is responding to infection or inflammation, breath testing can reveal how gut microbes are responding to the food and drink we consume.

The interesting point is that this signal often appears much earlier than other markers of health. For example, nutritional deficiencies such as low iron or low vitamin B12 can take months or even years to develop before they are detected in blood tests. But changes in microbial fermentation can occur much more quickly, reflecting the daily interaction between diet, hydration, gut motility and microbial activity.

In that sense, microbial fermentation may provide one of the earliest signals that something in our digestive habits is not working well.

Why “Healthy Foods” Sometimes Cause Symptoms

One of the most common questions people ask is: “Why do I react to foods that are supposed to be healthy?”

  • The answer is surprisingly simple: healthy does not always mean symptom-free.

Foods such as fruit, beans, lentils, whole grains and many vegetables are rich in fibre and nutrients2. These foods are beneficial for long-term health and support the growth of beneficial microbes in the gut.

However, they are also fermentable. For people with slower gut movement, increased microbial activity in the small intestine, or heightened gut sensitivity, fermentation of these foods may produce more gas than the body comfortably tolerates1.

This does not mean those foods are harmful or should be permanently avoided. It simply means that digestion sometimes requires a more personalised approach, including attention to portion size, timing, food combinations and underlying digestive function. Understanding these patterns is where breath testing can sometimes be helpful.

Hydration: The Forgotten Partner of Fibre

Another question I frequently hear is whether drinking more water can help symptoms such as constipation or bloating. Hydration alone is rarely a complete solution, but it plays a crucial role in maintaining normal digestive function.

Adequate fluid intake supports healthy bowel movement and gut motility. When the body is dehydrated, the intestines absorb more water from the stool, making it harder and more difficult to pass.

Hydration also becomes particularly important when people increase fibre intake. Fibre and fluid work together. Increasing fibre rapidly without increasing fluid can sometimes make symptoms feel worse, especially in people with sensitive digestive systems.

For most adults, general NHS guidance suggests roughly 6 to 8 glasses of fluid per day3, though individual needs vary depending on activity level, environment and health status. A simple daily indicator of hydration is urine colour, pale yellow generally indicates adequate hydration3.

Another useful indicator of digestive health is the Bristol stool chart4, which describes stool consistency. It is a simple but surprisingly helpful way of monitoring how well the digestive system is functioning4.

These simple daily observations, hydration, stool pattern, and symptoms, can act as basic “thermometers” of gut health. Breath testing simply provides a more advanced version of this thermometer, offering deeper insight into microbial fermentation patterns, when the basic thermometers are not sufficient anymore1.

Why Testing Before Treatment Matters1

When people experience persistent digestive symptoms, they often feel tempted to experiment with probiotics, restrictive diets, or various supplements. Trying something new can feel proactive. However, in some situations this approach may not address the underlying cause and can occasionally make symptoms worse.

For example, if someone already has excessive microbial activity in the small intestine, adding more bacteria through probiotics may not always be beneficial. Similarly, eliminating large groups of foods without a clear reason can lead to unnecessary dietary restriction and reduced nutritional balance.

Restrictive diets may sometimes reduce symptoms temporarily, but they can also reduce the intake of important nutrients such as fibre, vitamins and minerals, all of which support long-term gut and overall health. In addition, overly restrictive eating patterns may deprive the beneficial microbes in the gut of the nutrients they rely on for their normal activity and balance.

A more rational approach is to test first, understand the underlying mechanism, and then treat accordingly. This is where tools such as hydrogen–methane breath testing can provide valuable information5,6.

Breath testing should always be interpreted carefully within the clinical context, to ensure accurate results5,6. It remains the only validated clinical test that provides a functional assessment of microbial fermentation activity in the gut1. Unlike many emerging microbiome analyses, which are currently not standardised or reliable enough to guide treatment decisions, breath testing can help identify patterns such as carbohydrate malabsorption, abnormal fermentation, or possible bacterial overgrowth when used appropriately.

These insights can guide more targeted management rather than trial-and-error approaches, especially, if you are really suffering from the symptoms.

A Note on IBS, Stress and Unexplained Symptoms7

Another important point is that conditions such as irritable bowel syndrome (IBS) must be considered as diagnoses of exclusion. In practice, this means that when major structural or inflammatory diseases have been ruled out, completely, then, symptoms may be grouped under the IBS label.

However, this does not mean the symptoms are imaginary or simply due to stress. While stress can influence gut function, it is often too simplistic to attribute persistent symptoms to psychological factors alone. In practice, almost any symptom can be linked to stress if we stop looking for other explanations! In the same way, many gut symptoms can quickly be labelled as IBS!

In many cases, subtle physiological mechanisms, such as altered gut motility, microbial fermentation, gut hypersensitivity, or food intolerance, may be contributing to symptoms even when routine tests appear normal1. Advances in gut physiology and microbiome research are gradually helping us understand these mechanisms better.

Practical Advice for Hydration and Nutrition Week

For Hydration and Nutrition Week, my message is simple.

  1. Drink fluids regularly throughout the day rather than all at once3.

Use urine colour as a simple guide to hydration.

  • Include fibre in your diet but increase it gradually to avoid developing symptoms2.

Use stool pattern as a simple guide to fibre intake.

  • If you have persisting symptoms despite eating and drinking well, consider whether there may be an underlying reason that deserves further investigation1.

Use Hydrogen-Methane Breath Test as a validated medical grade guide to the root causes.

Digestive symptoms are rarely random. The body always has a reason for them.

In everyday life we already use simple “thermometers” of gut health, urine colour can suggest hydration, and stool patterns can reflect gut movement. At a deeper level, hydrogen–methane breath testing can act as a functional thermometer of microbial activity and your diet in the gut1.

Sometimes, the answers to persistent digestive symptoms can be found not only in what we eat and drink, but also in what our breath quietly reveals about the inner workings of our gut.

This hydration and nutrition week, take control of your gut health. If you are experiencing persistent gut issues, consult a healthcare professional and ask about breath testing. Hydrogen and methane breath testing (HMBT) with devices like the Gastrolyzer® range offer a non-invasive insight into gut health and can aid investigation or diagnosis in a clinical setting or from the comfort of your own home.

To learn more about the Gastrolyzer® range, visit the website here. Dr Jafari’s book ‘The Essential Guide to Hydrogen and Methane Breath Testing’ covers HMBT in detail, if you would like to learn more visit the webpage here.

References:

  1. Jafari J. 2025. The Essential Guide to Hydrogen and Methane Breath Testing: The Modern Non-Invasive Approach to Investigating Gastrointestinal Disorders. Bedfont Scientific Ltd, United Kingdom.
  2. NHS. How to get more fibre into your diet. Available at: https://www.nhs.uk/live-well/eat-well/how-to-get-more-fibre-into-your-diet/ (Accessed: 16th March 2026).
  3. NHS. Water, drinks and your health. Available at:
    https://www.nhs.uk/live-well/eat-well/water-drinks-nutrition/ (Accessed: 16th March 2026).
  4. Yaseen S, Abuelass FK, kamaleldien mohamed Abuelass F. Improving Documentation of Bowel Movements Using the Bristol Stool Chart: A Quality Improvement Project in a District General Hospital in the United Kingdom. Cureus. 2026 Jan 6;18(1).
  5. Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S, Schmulson M, Valdovinos M, Zakko S, Pimentel M. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American consensus. Official journal of the American College of Gastroenterology| ACG. 2017 May 1;112(5):775-84.
  6. Pimentel M, Saad RJ, Long MD, Rao SS. ACG clinical guideline: small intestinal bacterial overgrowth. Official journal of the American College of Gastroenterology| ACG. 2020 Feb 1;115(2):165-78.
  7. National Institute for Health and Care Excellence (NICE). Irritable bowel syndrome in adults: diagnosis and management (CG61). Available at: https://www.nice.org.uk/guidance/cg61 (Accessed: 16th March).

Shortlisting recognises Bedfont’s role in driving innovation and technology leadership across Kent.

Bedfont CTO Shortlisted at National Technology Awards

Scott Deamer-Smith, Chief Technology Officer (CTO) at Bedfont® Scientific Limited, has been recognised for his outstanding contribution to innovation and technology. Scott has spent an impressive 18 years of his career at Bedfont®, a med-tech company which specialises in the development of medical breath analysis devices and is thrilled to have been shortlisted in the Technology Leader of the Year category at this year’s National Technology Awards.

The awards are an annual UK programme hosted by National Technology News, designed to celebrate outstanding achievement and innovations in the technology sector. It spotlights companies, projects, products and leaders that drive technological progress and transformation across industries.

Scott Deamer-Smith, Chief Technology Officer at Bedfont® Scientific, comments, “I’m honoured to be recognised in the Technology Leader of the Year category and see it as a reflection of the strength of the team around me. At Bedfont®, innovation is something we create together every day, built on empowering people, encouraging curiosity & supporting bold ideas. This shortlisting represents the shared commitment & dedication of our technical team & the wider business. I’m incredibly proud of what we continue to accomplish together.”

To be considered in the Technology Leader of the Year category, individuals must demonstrate how they lead by example and inspire those around them to tackle the issues facing their business with innovative strategies and thoughtful staff development. Scott leads the technical department at Bedfont®, and its success is very much the result of his continued vision and commitment to driving technology development across the business.

“I count myself incredibly lucky to have seen Scott evolve since we were kids. Even back then, he was beating everyone in class with his technical prowess.” Said Jason Smith, CEO at Bedfont®. “Bedfont® has benefited enormously from his big brain, relentless curiosity and determination to push boundaries. If the judges manage to glean even a small part of the contribution he’s made, not just to our company, but to the wider industry, then there’s really only one winner.”

Bedfont®, a world leader in breath analysis, is incredibly proud of Scott’s achievement. The innovative med-tech company prides itself on staff development and actively encourages career growth with a dedicated training budget available to all staff. Scott joined Bedfont® in 2007 as an IT and Technical Support Engineer and, throughout his career at Bedfont®, has been given numerous opportunities to advance, culminating in his leadership of the technical department as Chief Technology Officer.

Winners will be announced at the awards ceremony on Thursday, 14th May at the London Marriott Hotel, where leading businesses and individuals will gather to celebrate this year’s outstanding achievements. To learn more about Bedfont® and its commitment to innovation, visit the website here.

Back to top